There are currently 82 active clinical trials seeking participants for Atrial Fibrillation research studies. The states with the highest number of trials for Atrial Fibrillation participants are Florida, California, Ontario and Texas.
Get With the Guidelines Atrial Fibrillation Registry
Recruiting
Get With The Guidelines-Atrial Fibrillation is designed to assist hospital care teams in consistently providing the latest evidence-based treatment for their AFib patients. At the same time, it offers a means of monitoring the quality of AFib care in U.S. hospitals and building a database for continued research and further quality improvement.
Gender:
ALL
Ages:
Between 18 years and 125 years
Trial Updated:
01/27/2025
Locations: Amy Bennett, Dallas, Texas
Conditions: Atrial Fibrillation, Atrial Flutter
Atrial Fibrosis in Obstructive Sleep Apnea Patients: A Pilot Study
Recruiting
The investigators hypothesize that Obstructive Sleep Apnea (OSA) is an independent risk factor for atrial fibrosis development. The investigators aim to prove the presence of atrial fibrosis on Delayed Enhancement Magnetic Resonance Imaging (DE-MRI) in OSA patients without atrial fibrillation (AF).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/23/2025
Locations: East Jefferson General Hospital, New Orleans, Louisiana +1 locations
Conditions: Atrial Fibrillation, Obstructive Sleep Apnea
SIMPLAAFY Clinical Trial
Recruiting
The primary objective is to demonstrate the safety and effectiveness of two monotherapy regimens versus dual antiplatelet (DAPT) therapy following post-implant with the WATCHMAN FLX Pro device in a commercial clinical setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: Tucson Medical Center Healthcare, Tucson, Arizona +16 locations
Conditions: Atrial Fibrillation, Stroke, Bleeding
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
Recruiting
This phase II trial studies how well amiodarone works in the prevention of atrial fibrillation (AF) after a minimally invasive esophagectomy (MIE) in patients with esophageal cancer. Atrial fibrillation (AF) is an irregular heart rhythm, usually associated with a rapid rate, that is caused by abnormal electrical activity within the atria. AF is the most common complication after MIE for esophageal cancer. There has never been a study of AF after MIE that has used unbiased assignment of patients... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/13/2025
Locations: OHSU Knight Cancer Institute, Portland, Oregon
Conditions: Atrial Fibrillation, Esophageal Carcinoma
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
Recruiting
The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Advanced Cardiovascular, LLC, Alexander City, Alabama +1035 locations
Conditions: Atrial Fibrillation
PULSED AF Post-Approval Study
Recruiting
PULSED AF PAS is a prospective, global, multi-center, non-randomized, observational trial. Subjects will be treated with the PulseSelect™ PFA System and followed through 36 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/08/2025
Locations: Northwell Health Lenox Hill Hospital, New York, New York +1 locations
Conditions: Atrial Fibrillation
Amplatzer Amulet LAAO vs. NOAC
Recruiting
The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy. The clinical investigation is a prospective, randomized, multicenter active control worldwide trial. Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device ("Device Group") and a commercially available NOAC medication ("Cont... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/08/2025
Locations: University Hospital - Univ. of Alabama at Birmingham (UAB), Birmingham, Alabama +131 locations
Conditions: Atrial Fibrillation, Stroke, Bleeding
The CONFORM Pivotal Trial
Recruiting
The CLAAS® device will be evaluated for safety and efficacy by establishing its performance is non-inferior to the commercially available WATCHMAN® and Amulet™ left atrial appendage closure devices in patients with non-valvular atrial fibrillation. Patients who are eligible for the trial will be randomized to receive either the CLAAS device or the WATCHMAN or Amulet™ devices and will be followed for 5 years after device implant.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/06/2025
Locations: Grandview Medical Center, Birmingham, Alabama +51 locations
Conditions: Atrial Fibrillation, Stroke
Defining the Risk of Ventricular Tachycardia in Genetic Forms of Early-onset Atrial Fibrillation
Recruiting
To use programmed ventricular stimulation at the time of AF ablation to define the prevalence and mechanism of inducible ventricular tachycardia (VT); pace-mapping to define the site of origin of ventricular arrhythmias; and voltage mapping to define low voltage scar substrate in the basal LV in patients with pathogenic TTN variants compared to genotype-negative controls.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/05/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Ventricular Tachycardia, Atrial Fibrillation
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
Recruiting
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/02/2025
Locations: University of Alabama Hospital, Birmingham, Alabama +167 locations
Conditions: Intracerebral Hemorrhage, Atrial Fibrillation
Non-Invasive Median Nerve Stimulation to Attenuate Atrial Tachyarrhythmias After Catheter Ablation for Atrial Fibrillation
Recruiting
Determine the role of vagal/median nerve stimulation using the CardiaCare RR2 home care wearable neuromodulation system on suppressing atrial arrhythmias and related symptoms in patients who have undergone AF ablation. The study population will be comprised of adults (age ≥18 yrs.) who have undergone AF ablation for paroxysmal or persistent AF. The study will assess the ability of neuromodulation, using the CardiaCare RR2 home care wearable, to suppress the following: 1. early (0-2 months) pos... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2024
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Atrial Fibrillation
Advanced Cardiac Imaging To Predict Embolic Stroke On Brain MRI: A Pilot Study
Recruiting
Demonstrating the pathophysiological link between Left Atrial (LA) and Left Atrial Appendage (LAA) pathology and embolic strokes in non-Atrial Fibrillation (AF) individuals represents a major advance in stroke prevention strategies. Instead of relying on non-specific criteria for stroke risk assessment, the investigators propose to identify individuals with high-risk of embolic stroke using imaging criteria that reflect the underlying pathophysiology of embolic stroke of cardiac origin. the inve... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
12/18/2024
Locations: Tulane University Medical Center, New Orleans, Louisiana
Conditions: Atrial Fibrillation, Stroke, Stroke, Cardiovascular, Vascular Cognitive Impairment, Strokes Thrombotic, Stroke, Ischemic